Q (haiku): Are TP53 mutations clinically actionable?

═ answer (success)
I appreciate the question, but I need to clarify the scope of what I can answer reliably.

**What I can tell you from cBioPortal:**
- Frequency of TP53 mutations across cancer types and studies
- Co-mutation patterns (which genes are altered together with TP53)
- Clinical attributes associated with TP53-mutant samples (age, stage, outcome in the dataset)
- Whether specific TP53 variants are annotated as drivers in the database

**What I cannot tell you:**
Clinical actionability requires interpretation of drug-response data, regulatory approval status, clinical trial evidence, and institutional guidelines — all beyond cBioPortal's scope. That's a question for oncology literature, treatment guidelines (NCCN, ASCO), or a clinical genomics team.

---

**If you want to explore TP53 in cBioPortal,** I can help you:
1. **Search for TP53 mutations** in a specific cancer type or study (e.g., "How frequent are TP53 mutations in lung adenocarcinoma?")
2. **Visualize TP53-mutant vs wildtype samples** — clinical features, outcomes, co-altered genes
3. **Check for OncoKB driver annotations** on specific TP53 variants
4. **Link to external resources** (OncoKB, ClinVar, etc.) if available in the database

Which of these would be useful? Or if you have a more specific clinical question (e.g., "In BRCA tumors, what are the most common TP53 variants?"), I can query that data for you.